Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.
By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.
GlobalData on MSN11d
Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drugThe trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...
The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results GlobeNewswire September 05, 2024 Ingelheim, Germany and Basel ...
GlobalData on MSN1mon
Boehringer Ingelheim acquires Nerio Therapeutics for $1.3bnBoehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. The acquisition ...
INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback